NGS panels are a powerful tool for parallel assessment of genomic integrity and expression across multiple targets. This facilitates biomarker discovery in early phase clinical trials and also subsequent development of CDx assays with potential utility across multiple drug targets.

In this webinar, Dr Cheryl McFarlane, Operations Manager at Almac Diagnostic Services will summarise the main considerations of development and analytical validation of such panels and describe our experience identifying important technical and regulatory challenges.

Topics covered include:

• Use of NGS panels for patient selection
• Biomarker Discovery pathway in early phase trials
• A customised CDx Development approach
• Regulatory challenges and solutions